Clinical efficacy of etanercept for treatment of PAPA syndrome.
Tofteland
Nathan D
ND
Department of Internal Medicine, University of Kansas School of Medicine-Wichita, Wichita, KS 67214, USA. ntofteland@kumc.edu
Shaver
Timothy S
TS
D000152:Acne Vulgaris / Q000188:drug therapy; D001170:Arthritis, Infectious / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013577:Syndrome; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept